NasdaqGM:URGNBiotechs
UroGen Pharma (URGN) Stock Looks Fairly Priced Despite Its 210% Run
UroGen Pharma stock has delivered very strong share price returns over the past five years, yet its current valuation checks and market multiples now suggest the shares are closer to fairly priced than a clear bargain.
UroGen Pharma has returned about 210% over the last 5 years, which puts recent gains front and center when judging whether the current price already reflects much of that success.
Expectations around UroGen Pharma’s ability to grow revenue and eventually convert its pipeline...